Top Analyst Reports for Merck, Palo Alto & Freeport

14.08.25 22:46 Uhr

Werte in diesem Artikel
Aktien

75,90 EUR -0,90 EUR -1,17%

117,70 EUR -2,25 EUR -1,88%

Indizes

PKT PKT

PKT PKT

2.064,4 PKT 25,4 PKT 1,24%

2.151,8 PKT 27,2 PKT 1,28%

24.422,6 PKT 308,9 PKT 1,28%

9.149,7 PKT 115,7 PKT 1,28%

1.949,3 PKT 19,5 PKT 1,01%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

201,8 PKT 1,7 PKT 0,86%

46.530,6 PKT 89,5 PKT 0,19%

594,1 PKT 5,6 PKT 0,95%

12.837,8 PKT 157,7 PKT 1,24%

24.481,5 PKT 256,5 PKT 1,06%

24.419,6 PKT 227,1 PKT 0,94%

18.051,2 PKT 64,8 PKT 0,36%

9.422,9 PKT 116,3 PKT 1,25%

16.719,4 PKT 126,2 PKT 0,76%

3.346,2 PKT 0,9 PKT 0,03%

6.716,3 PKT 5,1 PKT 0,08%

24.490,1 PKT 283,0 PKT 1,17%

Thursday, August 14, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Merck & Co., Inc. (MRK), Palo Alto Networks, Inc. (PANW) and Freeport-McMoRan Inc. (FCX), as well as a micro-cap stock Espey Mfg. & Electronics Corp. (ESP). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>> Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens,  attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Economic Data at 3-Year Highs: PPI, Jobless ClaimsToday's Featured Research ReportsShares of Merck have underperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (-15.7% vs. -4.2%). Rising competitive and generic pressure on some drugs and persistent challenges for Gardasil in China remain overhangs for the company. There are concerns about Merck’s ability to successfully navigate the Keytruda loss of exclusivity and potential competition for the drug. Nevertheless, Merck’s second-quarter earnings beat estimates while sales met. Its blockbuster drug, Keytruda, and new products have been driving sales. With label expansion into new indications, particularly earlier-stage launches, Keytruda is expected to see continued growth. Animal health is also contributing to growth. Merck has been making meaningful pipeline progress. It is also actively pursuing M&A deals to enhance its pipeline and diversify away from Keytruda.(You can read the full research report on Merck here >>>)Palo Alto’s shares have gained +2.6% over the past year against the Zacks Security industry’s gain of +21%. The company has been benefiting from continuous deal wins and the increasing adoption of its next-generation security platforms, which are attributable to the rise of the hybrid work trend and the heightened need for stronger security.PANW’s strong back-to-back quarterly performances reflect its sustained focus on product innovation, a shift in its business model to subscription-based services, platform integration and continued investments in the go-to-market strategy. The normalization of the supply chain is also aiding growth across the Products, Services and Subscription segments. However, softening IT spending amid macroeconomic headwinds may hurt its near-term prospects. Forex headwinds and higher marketing and sales expenses are likely to continue hurting its profitability. Also, high acquisition-related expenses are denting margins.(You can read the full research report on Palo Alto here >>>)Shares of Freeport have outperformed the Zacks Mining - Non Ferrous industry over the year-to-date period (+11% vs. +6.8%). The company’s adjusted earnings and sales for the second quarter beat the respective Zacks Consensus Estimate. Freeport is conducting exploration activities near existing mines to expand reserves. It is expected to gain from progress in exploration activities that will boost production capacity. Freeport is executing several smelter projects in Indonesia. It is also well-positioned to benefit from automotive electrification, which is positive for copper, as electric vehicles are copper-intensive. The company's efforts to reduce debt are also encouraging. However, weak copper volumes may also hurt its performance. Sizable capital spending is also likely to impact free cash flow generation. Copper prices also remain volatile amid trade uncertainties.(You can read the full research report on Freeport here >>>)Espey Mfg. & Electronics’ shares have outperformed the Zacks Electronics - Military industry over the year-to-date period (+59.6% vs. -20.7%). This microcap company with a market capitalization of $134.46 million posted strong YTD FY25 results, with revenue up 26.7% to $34.4 million, driven by defense power supply programs and improved gross margins. Its record $138 million backlog — anchored by long-term contracts and key customer relationships — provides multi-year revenue visibility, with nearly half scheduled beyond FY26. Strategic wins include $49.3 million in multi-year contracts for the U.S. Navy’s Columbia-class submarines, supporting long-term positioning in electrification systems. A debt-free balance sheet, $28.3 million in liquidity, and $10.8 million in federal funding for capacity upgrades enhance strategic flexibility and throughput. Espey benefits from defense modernization tailwinds, especially in naval and airborne electrification. However, risks include persistent margin headwinds from early-stage programs, fixed cost pressures, and high customer concentration. (You can read the full research report on Espey Mfg. & Electronics here >>>)Other noteworthy reports we are featuring today include Telefónica, S.A. (TEF), PPL Corp. (PPL) and Antero Midstream Corp. (AM).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadKeytruda Drives Merck (MRK) Sales Amid Gardasil IssuesPalo Alto (PANW) Rides on Shift to Subscription ServicesExploration Progress, Debt Reduction to Aid Freeport (FCX)Featured ReportsTelefonica (TEF) Rides on Robust 5G Coverage Amid Forex WoesPer the Zacks analyst, Telefonica's extensive 5G footprint across Spain, Germany and Brazil is solidifying its position. However, global macroeconomic uncertainty and forex volatility are concerning.Investments, Clean Generation Focus Aid PPL Corporation (PPL)Per the Zacks analyst, PPL's strategic investment of $20 billion during 2025-2028 should strengthen its infrastructure. Focus on renewables projects should further boost margins.Antero Midstream (AM) Shines on Fee-Based Revenue StabilityPer the Zacks analyst, Antero Midstream's long-term fee-based contracts ensure predictable cash flows, supporting steady dividends, debt reduction, and sustained shareholder value in 2025.Strong Solvency, New Launches Boost Globus Medical (GMED)Globus Medical exited the second quarter of 2025 with no long-term debt, boasting solid financial stability amid an overall tough macroeconomic landscape. Furthermore, new product launches aid growth.Fee Income to Support Bank OZK (OZK), Asset Quality WeakPer the Zacks analyst, fee income, high rates, efforts to boost mortgage banking business and diverse loans will likely aid Bank OZK's financials. Yet, weak asset quality and high costs are woes.New UpgradesLow Fuel Costs & Fleet Upgrade Efforts Aid SkyWest (SKYW)The Zacks analyst likes the company's efforts to modernize its fleet. Low fuel costs are aiding the regional carrier's bottom line.Wolverine's (WWW) Product Initiatives to Boost Market SharePer the Zacks analyst, Wolverine is actively pursuing a comprehensive strategy to enhance brand portfolio, focusing on Merrell and Saucony brands. These efforts are expected to help gain market share.New DowngradesAI Tax Assist Benefits H&R Block (HRB) Amid Low LiquidityPer the Zacks Analyst, integration of a generative AI-powered technology, AI Tax Assist, in H&R Block's DIY tax preparation boosts top line. Low liquidity is concerning.Inflation, Tariffs, and Costs Strain Carter's (CRI) MarginsPer the Zacks analysts, Carter's profitability remains pressured as cost inflation, higher clearance activity, tariffs, and FX headwinds continue to weigh on margins despite strategic investments.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PPL Corporation (PPL): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Freeport-McMoRan Inc. (FCX): Free Stock Analysis Report Telefonica SA (TEF): Free Stock Analysis Report Antero Midstream Corporation (AM): Free Stock Analysis Report Palo Alto Networks, Inc. (PANW): Free Stock Analysis Report Espey Mfg. & Electronics Corp. (ESP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Merck und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Freeport

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Freeport

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Merck KGaA

Wer­bung

Analysen zu Merck KGaA

DatumRatingAnalyst
25.09.2025Merck OverweightJP Morgan Chase & Co.
12.09.2025Merck Market-PerformBernstein Research
25.08.2025Merck Market-PerformBernstein Research
19.08.2025Merck Equal WeightBarclays Capital
11.08.2025Merck BuyDeutsche Bank AG
DatumRatingAnalyst
25.09.2025Merck OverweightJP Morgan Chase & Co.
11.08.2025Merck BuyDeutsche Bank AG
11.08.2025Merck BuyUBS AG
08.08.2025Merck BuyGoldman Sachs Group Inc.
08.08.2025Merck KaufenDZ BANK
DatumRatingAnalyst
12.09.2025Merck Market-PerformBernstein Research
25.08.2025Merck Market-PerformBernstein Research
19.08.2025Merck Equal WeightBarclays Capital
01.08.2025Merck Market-PerformBernstein Research
28.07.2025Merck Market-PerformBernstein Research
DatumRatingAnalyst
06.03.2023Merck VerkaufenDZ BANK
02.03.2023Merck SellGoldman Sachs Group Inc.
07.02.2023Merck SellGoldman Sachs Group Inc.
02.02.2023Merck VerkaufenDZ BANK
15.11.2022Merck SellGoldman Sachs Group Inc.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Merck KGaA nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen